Telescope Innovations Corp.
Telescope Innovations Corp., a chemical technology company, develops manufacturing processes and tools for the pharmaceutical and chemical industry in the United States and Canada. It offers DIRECTINJECT-LCTM, a hardware and software ecosystem that enables direct sampling and analysis of chemical reactions. It also provides intellectual property and contract research services. It serves pharmaceu… Read more
Telescope Innovations Corp. (TELIF) - Net Assets
Latest net assets as of November 2025: $5.89 Million USD
Based on the latest financial reports, Telescope Innovations Corp. (TELIF) has net assets worth $5.89 Million USD as of November 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.43 Million) and total liabilities ($4.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.89 Million |
| % of Total Assets | 56.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | -47.65% |
| 10-Year Change | N/A |
| Growth Volatility | 46.85 |
Telescope Innovations Corp. - Net Assets Trend (2019–2025)
This chart illustrates how Telescope Innovations Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Telescope Innovations Corp. (2019–2025)
The table below shows the annual net assets of Telescope Innovations Corp. from 2019 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | $2.00 Million | +32.01% |
| 2024-08-31 | $1.52 Million | -41.13% |
| 2023-08-31 | $2.58 Million | +54.10% |
| 2022-08-31 | $1.67 Million | -56.29% |
| 2021-08-31 | $3.83 Million | +3971.02% |
| 2020-08-31 | $-98.85K | 0.00% |
| 2019-08-31 | $-98.85K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Telescope Innovations Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1339902300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.34 Million | 515.98% |
| Other Comprehensive Income | $3.47 Million | 173.25% |
| Other Components | $1.83 Million | 91.22% |
| Total Equity | $2.00 Million | 100.00% |
Telescope Innovations Corp. Competitors by Market Cap
The table below lists competitors of Telescope Innovations Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ONCOARENDI THERAP ZY-01
F:1B1
|
$21.15 Million |
|
ES SUNLOGY BERHAD
KLSE:0345
|
$21.16 Million |
|
CLOUD TECHNOL.AB ZY -10
F:42T
|
$21.17 Million |
|
PT Satu Visi Putra Tbk
JK:VISI
|
$21.17 Million |
|
Cosmos Yatirim Holding AS
IS:COSMO
|
$21.13 Million |
|
Bexil Cp
PINK:BXLC
|
$21.12 Million |
|
Lay Hong Bhd
KLSE:9385
|
$21.12 Million |
|
Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares
NASDAQ:AZI
|
$21.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Telescope Innovations Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,517,282 to 2,003,000, a change of 485,718 (32.0%).
- Net loss of 1,562,812 reduced equity.
- Other comprehensive income increased equity by 3,470,114.
- Other factors decreased equity by 1,421,584.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.56 Million | -78.02% |
| Other Comprehensive Income | $3.47 Million | +173.25% |
| Other Changes | $-1.42 Million | -70.97% |
| Total Change | $- | 32.01% |
Book Value vs Market Value Analysis
This analysis compares Telescope Innovations Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.66x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-08-31 | $0.00 | $0.29 | x |
| 2020-08-31 | $0.00 | $0.29 | x |
| 2021-08-31 | $0.08 | $0.29 | x |
| 2022-08-31 | $0.03 | $0.29 | x |
| 2023-08-31 | $0.05 | $0.29 | x |
| 2024-08-31 | $0.03 | $0.29 | x |
| 2025-08-31 | $0.04 | $0.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Telescope Innovations Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -78.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -32.72%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 3.63x
- Recent ROE (-78.02%) is above the historical average (-106.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-243.09K |
| 2021 | -105.20% | 0.00% | 0.00x | 1.06x | $-4.41 Million |
| 2022 | -343.61% | -965.24% | 0.20x | 1.81x | $-5.91 Million |
| 2023 | -27.86% | -25.43% | 0.86x | 1.28x | $-975.83K |
| 2024 | -87.24% | -31.03% | 0.75x | 3.75x | $-1.48 Million |
| 2025 | -78.02% | -32.72% | 0.66x | 3.63x | $-1.76 Million |
Industry Comparison
This section compares Telescope Innovations Corp.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Telescope Innovations Corp. (TELIF) | $5.89 Million | 0.00% | 0.77x | $21.14 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |